Precigen (PGEN) Short term Debt (2013 - 2023)
Precigen's (PGEN) quarterly Short term Debt came in at $13.8 million in Q1 2023, up 8326.22% year-over-year from $164000.0 in Q1 2022, and down 68.03% quarter-over-quarter from $43.2 million in Q4 2022.
Analysis
Precigen (PGEN) Short term Debt (2013 - 2023) Analysis & Trends
Precigen (PGEN) has reported Short term Debt for 11 consecutive years, with $13.8 million the latest figure, recorded in Q1 2023.
- On a quarterly basis, Short term Debt rose 8326.22% year-over-year to $13.8 million in Q1 2023; TTM through Mar 2023 was $13.8 million, a 8326.22% increase from a year earlier, with the FY2022 full-year figure at $43.2 million, up 83013.46% from the prior year.
- Short term Debt was $13.8 million for Q1 2023 at Precigen, down from $43.2 million in the prior quarter.
- Over five years, Short term Debt peaked at $82.1 million in Q3 2022 and troughed at $52000.0 in Q4 2021.
- A 5-year average of $15.9 million and a median of $468000.0 in 2019 frame the typical range for Short term Debt.
- Across the five-year window, Short term Debt slumped 98.89% in 2021 and surged 83013.46% in 2022, its largest moves.
- Over 5 years, Short term Debt stood at $31.7 million in 2019, then plunged by 98.86% to $360000.0 in 2020, then sank by 85.56% to $52000.0 in 2021, then surged by 83013.46% to $43.2 million in 2022, then tumbled by 68.03% to $13.8 million in 2023.
- The last three Short term Debt figures came in at $13.8 million (Q1 2023), $43.2 million (Q4 2022), and $82.1 million (Q3 2022), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Krystal Biotech | 10.27 Bn | 9.43 Bn | 112.79 Mn |
| 2 | CRISPR Therapeutics AG | 5.17 Bn | 5.17 Bn | - |
| 3 | Iovance Biotherapeutics | 3.79 Bn | 3.49 Bn | 55.72 Mn |
| 4 | Legend Biotech | 3.68 Bn | 2.71 Bn | 251.50 Mn |
| 5 | uniQure | 3.05 Bn | 3.05 Bn | 5.49 Mn |
| 6 | Beam Therapeutics | 2.65 Bn | 2.65 Bn | - |
| 7 | Precigen | 2.44 Bn | 2.44 Bn | 52.17 Mn |
| 8 | Sarepta Therapeutics | 2.33 Bn | 1.53 Bn | 251.87 Mn |
| 9 | Vericel | 1.99 Bn | 1.83 Bn | 56.40 Mn |
| 10 | Taysha Gene Therapies | 1.97 Bn | 1.97 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2023 | 13.82 Mn |
| Dec 31, 2022 | 43.22 Mn |
| Sep 30, 2022 | 82.07 Mn |
| Jun 30, 2022 | 277,000.00 |
| Mar 31, 2022 | 164,000.00 |
| Dec 31, 2021 | 52,000.00 |
| Sep 30, 2021 | 355,000.00 |
| Jun 30, 2021 | 356,000.00 |
| Mar 31, 2021 | 359,000.00 |
| Dec 31, 2020 | 360,000.00 |
| Sep 30, 2020 | 421,000.00 |
| Jun 30, 2020 | 32.11 Mn |
| Mar 31, 2020 | 31.89 Mn |
| Dec 31, 2019 | 31.67 Mn |
| Sep 30, 2019 | 31.43 Mn |
| Jun 30, 2019 | 468,000.00 |
| Mar 31, 2019 | 564,000.00 |
| Dec 31, 2018 | 479,000.00 |
| Sep 30, 2018 | 546,000.00 |
| Jun 30, 2018 | 574,000.00 |